A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery

Trial Profile

A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Reparixin (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Sponsors Dompe Spa
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Apr 2016 Results assessing safety and biological effects presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 02 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top